year. The top 10 M&A deals of 2024 had a combined in 2024 to US$1,571M in 2025, far exceeding the value of Us$59.61 B and accounted for a slightly total deal value, which removes any distorting effects (46%). Nine of the top 10 acquisitions of 2025 were from outliers, increased by only a modest 6% from worth Us$10 B or more, up from only two in 2024 and, US$5 B and Us$10 B, there were five deals in this price Interestingly, of the top 10 M&A deals of 2025, as IQVIA Pharma Deals database, seven were announced purchase of cancer diagnostics firm, Exact Sciences, for Us$105 per common share, representing a total equity value of approximately US$21 B. Abbott picks up of the year. Combined, the top 10 M&A deals of 2025 had a total value of Us$135 B, equivalent to 53% of the Cologuard?, a noninvasive colorectal cancer screening